Long Term Clinical Outcome After Arthroscopic Rotator Cuff Repair Augmentation With Autologous Microfragmented Lipoaspirate Tissue
1 other identifier
observational
52
1 country
1
Brief Summary
Specific Aims : The aim of this prospective randomized controlled single-blind clinical trial was to evaluate the safety and efficacy of autologous microfragmented lipoaspirate tissue in arthroscopic rotator cuff repair. The primary goal of this study was to test the following hypothesis: an intraoperative injection of autologous microfragmented adipose tissue processed with an enzyme-free technology could improve the clinical outcomes of single-row arthroscopic rotator cuff repair in terms of points in the Constant-Murley score (CMS) collected at least 5 years after surgery. Background and Significance: Rotator cuff surgery was initially proposed at the end of the 19th century and evolved then from open to arthroscopic techniques, rising quickly from a minor niche to a fully recognized subspecialty. To improve clinical and functional results and reduce the retear rate, new fixation techniques and biological solutions to enhance tendon healing are being developed at a fast pace, as shown by the dramatic increase in the number of articles published per year. Biological solutions to enhance rotator cuff healing include growth factors and platelet-rich plasma, as well as mesenchymal stem cells (MSCs) and their derivatives. MSCs are believed to enhance tissue healing mainly through stimulation of local cells via paracrine mechanisms and anti-inflammatory and/or immunomodulatory activity, thus creating a suitable microenvironment for tissue repair. Autologous microfragmented lipoaspirate tissue has been recently introduced in orthopaedics as an easily available source of adipose derived MSCs (ADSCs) to support and accelerate tissue regeneration. Lipoaspirates contain human ADSCs and produce growth factors, such as platelet-derived growth factor, fibroblast growth factor, transforming growth factor beta, and vascular endothelial growth factor, which play important regulatory roles in cellular functions, including adhesion, chemotaxis, proliferation, migration, matrix synthesis, differentiation, and angiogenesis. Herewith, autologous microfragmented lipoaspirate tissue is expected to optimize the microenvironment for tendon regeneration. Among many approaches, devices relying on nonenzymatic methods and avoiding the use of additives and other additional manipulations (eg, centrifugation) allow one to harvest, process, and obtain autologous microfragmented lipoaspirate tissue directly in the operative theatre under sterile conditions. This permits immediate use in the same surgical intervention without delays owing to the difficulty of an ex vivo cell expansion and the complexity of the current good manufacturing practice requirements for preparing cells for therapeutic use. Although several animal studies have been published showing promising results for the use of ADSCs in enhancing the healing of rotator cuff tears, minimal evidence describing augmentation of rotator cuff treatment with lipoaspirate. Preliminary Studies/Progress Report: This study is a prospective, randomized, double-blind, controlled clinical trial and represents the final follow-up of an our previous study with short follow-up (2 years). The previous study demonstrated that the intraoperative injection of autologous microfragmented adipose tissue is safe and effective in improving short-term clinical and functional results after single-row arthroscopic rotator cuff repair. Nevertheless, no significant differences emerged between the groups in terms of rerupture rate, complication rate, number of adverse events, and mid-term clinical outcomes. A previous in vitro study showed that autologous microfragmented adipose tissue significantly increases the proliferation rate of human tendon stem cells without altering their stemness and differentiation capability. Moreover, treated cells increase the expression of VEGF, which is crucial for the neovascularization of the tissue during the healing process. Research Design and Method: At least 5 years after surgery, all enrolled patients in the previous study will be call again and will be asked to complete the ASES, SST, and VAS questionnaire and they will undergo a clinical examination, including the CMS and measurement of isometric strength in shoulder forward flexion, abduction, and external rotation. All strength measures will be performed in triplicate with a dynamometer. During the same assessment day, the patients would be evaluated with MRI of the operated shoulder in order to assess tendon integrity and calculate rerupture rate according to the classification proposed by Sugaya (types IV and V defined as retears). Atrophy of the supraspinatus muscle belly was evaluated according to Warner and fatty degeneration was classified according to Fuchs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 11, 2025
CompletedFirst Submitted
Initial submission to the registry
April 16, 2025
CompletedFirst Posted
Study publicly available on registry
May 7, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 11, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 11, 2026
April 28, 2026
April 1, 2026
1.5 years
April 16, 2025
April 27, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Comparison between the two groups of the incidence of retears at least 5 years after surgery
The primary goal of this study is to evaluate the long-term effecacy of the use of autologous microfragmented adipose tissue in arthroscopic rotator cuff repair, in terms of estimating the incidence of retears at least 5 years after surgery, as assessed by magnetic resonance imaging (MRI).
5 years
Secondary Outcomes (5)
Comparison of the Constant-Murley score (CMS) between the two groups at least 5 years after surgery.
5 years
Comparison between the two groups of the difference in the Visual Analogue Scale (VAS) score at least 5 years after surgery.
5 years
Comparison between the two groups of abduction and external rotation strength at least 5 years after surgery.
5 years
Comparison of the ASES (American Shoulder and Elbow Surgeons score) and SST (Simple Shoulder Test) between the two groups at least 5 years after surgery.
5 years
Comparison between the two groups of the progression of supraspinatus fatty degeneration at least 5 years after surgery
5 years
Study Arms (2)
Treatment group
Cohort of patients that receved a single-row arthroscopic rotator cuff repair, followed by intraoperative injection of autologous microfragmented adipose tissue processed with an enzyme-free technology, 5 years ago in our previous trial (NCT02783352).
Control group
Cohort of patients that received a single-row arthroscopic rotator cuff repair alone, 5 years ago in our previous trial (NCT02783352).
Interventions
All enrolled patients will be contacted again at a minimum follow-up of 5 years, and an MRI of the operated shoulder will also be performed.
All enrolled patients will be contacted again at a minimum follow-up of 5 years, and a clinical evaluation will be performed using the following measurements and scores: VAS, SST, ASES, CMS scores, and strength measurements in external rotation and abduction.
Eligibility Criteria
This study is a prospective, randomized, double-blind, controlled clinical trial and represents the final follow-up of an our previous study with short follow-up (2 years). At least 5 years after surgery, all enrolled patients in the previous study will be call again and will be asked to complete the ASES, SST, and VAS questionnaire and they will undergo a clinical examination, including the CMS and measurement of isometric strength in shoulder forward flexion, abduction, and external rotation. All strength measures will be performed in triplicate with a dynamometer. During the same assessment day, the patients would be evaluated with MRI of the operated shoulder in order to assess tendon integrity and calculate rerupture rate according to the classification proposed by Sugaya (types IV and V defined as retears). Atrophy of the supraspinatus muscle belly was evaluated according to Warner and fatty degeneration was classified according to Fuchs.
You may qualify if:
- Age \> 18 years
- Full-thickness supraspinatus and infraspinatus tendon tears (C1, C2, and C3 according to the SCOI classification)
- Indication for arthroscopic rotator cuff repair
- Informed consent to participate in the study
- Informed consent to participate for the duration of the study
You may not qualify if:
- Partial rotator cuff tendon tears (A1, A2, A3, B1, B2, and B3 according to the SCOI classification)
- Massive rotator cuff tear (C4 according to the SCOI classification)
- Subscapularis tendon tear (grade III, IV, or IV according to Lafosse classification)
- Associated anterior, posterior, or multidirectional shoulder instability
- Indication for repair of a SLAP lesion of the biceps anchor
- Grade III or IV muscle atrophy of the supraspinatus and infraspinatus tendons (according to Goutallier or Fuchs classification)
- Intra-articular hyaluronic acid or corticosteroid infiltration within 3 mo from the planned surgical procedure
- Medical comorbidities contraindicating arthroscopic shoulder surgery
- Local (shoulder, abdominal region, gluteal region) or systemic infection, osteomyelitis, or sepsis
- Diabetes mellitus, untreated thyroid disease, chronic kidney disease, rheumatoid arthritis
- Immunodeficiency
- Chronic disorders involving coagulation, platelet aggregation, or severe coagulopathy
- Severe cardiovascular disease
- Stroke or acute cardiovascular event within 6 mo from the planned surgical procedure
- Weight loss for any cause .30 kg in 12 mo or .10 kg in 12 mo without a cause
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
ASST Gaetano Pini-CTO
Milan, Italy, 20122, Italy
Related Publications (15)
Vigano M, Lugano G, Perucca Orfei C, Menon A, Ragni E, Colombini A, De Luca P, Randelli P, de Girolamo L. Autologous microfragmented adipose tissue reduces inflammatory and catabolic markers in supraspinatus tendon cells derived from patients affected by rotator cuff tears. Int Orthop. 2021 Feb;45(2):419-426. doi: 10.1007/s00264-020-04693-9. Epub 2020 Jul 8.
PMID: 32642826RESULTFuchs B, Weishaupt D, Zanetti M, Hodler J, Gerber C. Fatty degeneration of the muscles of the rotator cuff: assessment by computed tomography versus magnetic resonance imaging. J Shoulder Elbow Surg. 1999 Nov-Dec;8(6):599-605. doi: 10.1016/s1058-2746(99)90097-6.
PMID: 10633896RESULTWarner JJ, Higgins L, Parsons IM 4th, Dowdy P. Diagnosis and treatment of anterosuperior rotator cuff tears. J Shoulder Elbow Surg. 2001 Jan-Feb;10(1):37-46. doi: 10.1067/mse.2001.112022.
PMID: 11182734RESULTSugaya H, Maeda K, Matsuki K, Moriishi J. Repair integrity and functional outcome after arthroscopic double-row rotator cuff repair. A prospective outcome study. J Bone Joint Surg Am. 2007 May;89(5):953-60. doi: 10.2106/JBJS.F.00512.
PMID: 17473131RESULTRandelli P, Menon A, Ragone V, Creo P, Bergante S, Randelli F, De Girolamo L, Alfieri Montrasio U, Banfi G, Cabitza P, Tettamanti G, Anastasia L. Lipogems Product Treatment Increases the Proliferation Rate of Human Tendon Stem Cells without Affecting Their Stemness and Differentiation Capability. Stem Cells Int. 2016;2016:4373410. doi: 10.1155/2016/4373410. Epub 2016 Jan 6.
PMID: 27057170RESULTSoleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol. 2012 Jan;67(1):1-8. doi: 10.1111/j.1600-0897.2011.01069.x. Epub 2011 Sep 23.
PMID: 21951555RESULTShi M, Liu ZW, Wang FS. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol. 2011 Apr;164(1):1-8. doi: 10.1111/j.1365-2249.2011.04327.x. Epub 2011 Feb 24.
PMID: 21352202RESULTSchmitt A, van Griensven M, Imhoff AB, Buchmann S. Application of stem cells in orthopedics. Stem Cells Int. 2012;2012:394962. doi: 10.1155/2012/394962. Epub 2012 Feb 23.
PMID: 22550505RESULTMei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, Liles WC, Stewart DJ. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010 Oct 15;182(8):1047-57. doi: 10.1164/rccm.201001-0010OC. Epub 2010 Jun 17.
PMID: 20558630RESULTKrasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, Matthay MA. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010 Dec;28(12):2229-38. doi: 10.1002/stem.544.
PMID: 20945332RESULTGnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008 Nov 21;103(11):1204-19. doi: 10.1161/CIRCRESAHA.108.176826.
PMID: 19028920RESULTAngeline ME, Rodeo SA. Biologics in the management of rotator cuff surgery. Clin Sports Med. 2012 Oct;31(4):645-63. doi: 10.1016/j.csm.2012.07.003.
PMID: 23040551RESULTRandelli P, Randelli F, Ragone V, Menon A, D'Ambrosi R, Cucchi D, Cabitza P, Banfi G. Regenerative medicine in rotator cuff injuries. Biomed Res Int. 2014;2014:129515. doi: 10.1155/2014/129515. Epub 2014 Aug 13.
PMID: 25184132RESULTMcElvany MD, McGoldrick E, Gee AO, Neradilek MB, Matsen FA 3rd. Rotator cuff repair: published evidence on factors associated with repair integrity and clinical outcome. Am J Sports Med. 2015 Feb;43(2):491-500. doi: 10.1177/0363546514529644. Epub 2014 Apr 21.
PMID: 24753240RESULTRandelli P, Cucchi D, Ragone V, de Girolamo L, Cabitza P, Randelli M. History of rotator cuff surgery. Knee Surg Sports Traumatol Arthrosc. 2015 Feb;23(2):344-62. doi: 10.1007/s00167-014-3445-z. Epub 2014 Dec 2.
PMID: 25448135RESULT
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof., MD
Study Record Dates
First Submitted
April 16, 2025
First Posted
May 7, 2025
Study Start
April 11, 2025
Primary Completion (Estimated)
October 11, 2026
Study Completion (Estimated)
October 11, 2026
Last Updated
April 28, 2026
Record last verified: 2026-04